Article Information
History
- March 12, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Mayte Pérez-Olmeda1,
- José María Saugar1,
- Aurora Fernández-García1,2,
- Beatriz Pérez-Gómez2,3,
- Marina Pollán2,3,
- Ana Avellón1,2,
- Roberto Pastor-Barriuso2,3,
- Nerea Fernández-de Larrea2,3,
- Mariano Martín4,
- Israel Cruz5,
- Jose L Sanmartín4,
- Giovanni Fedele1,
- Jose León Paniagua6,
- Juan F Muñoz-Montalvo4,
- Faustino Blanco7,
- Raquel Yotti6,
- Jesús Oteo-Iglesias1,8,* and
- on behalf of the ENE-COVID Study Group†
- 1National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
- 2Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP)
- 3National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain
- 4Deputy Directorate of Information Technologies, Ministry of Health, Madrid, Spain
- 5National School of Public Health, Instituto de Salud Carlos III, Madrid, Spain
- 6Instituto de Salud Carlos III, Madrid, Spain
- 7General Secretary of Health, Ministry of Health, Madrid, Spain
- 8Spanish Network for Research in Infectious Diseases (REIPI)
- ↵*Corresponding author:
Jesús Oteo-Iglesias, National Centre for Microbiology, Instituto de Salud Carlos III, Carretera Pozuelo a Majadahonda, 28220 Majadahonda, Madrid, Spain., Phone: ++34 918 22 3650. Fax: ++34 915097966., Email: jesus.oteo{at}isciii.es
Posted March 12, 2021.
Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain
